Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry

Corinne Frere; Javier Trujillo-Santos; Carme Font; Ángel Sampériz; Roberto Quintavalla; José González-Martínez; Fernando Javier Vázquez; Jorge Lima; Dominique Farge; Manuel Monreal; for the RIETE Investigators

doi:10.1055/s-0038-1642009

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2018; 118(06): 1119-1122
DOI: 10.1055/s-0038-1642009

Letter to the Editor

Schattauer GmbH Stuttgart

Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry

Corinne Frere

¹Department of Haematology, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris, France

,

Javier Trujillo-Santos

²Department of Internal Medicine, Hospital General Universitario Santa Lucía, Murcia, Spain

,

Carme Font

³Department of Medical Oncology, Hospital Clínic, Barcelona, Spain

,

Ángel Sampériz

⁴Department of Internal Medicine, Hospital Reina Sofía, Tudela, Navarra, Spain

,

Roberto Quintavalla

⁵Department of Medicine 3, Azienda Ospedaliera Universitaria, Parma, Italy

,

José González-Martínez

⁶Department of Internal Medicine, ALTAHAIA, Xarxa Assistencial de Manresa, Barcelona, Spain

,

Fernando Javier Vázquez

⁷Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

,

Jorge Lima

⁸Department of Pneumonology, Hospital Universitario de Valme, Sevilla, Spain

,

Dominique Farge

⁹Internal Medicine Unit: Autoimmune and Vascular Diseases, UF 04, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

¹⁰University Paris Diderot, Paris, France

,

Manuel Monreal

¹¹Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

¹²Universidad Católica de Murcia, Murcia, Spain

,

for the RIETE Investigators

References
1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
2 Mahé I, Chidiac J, Bertoletti L. , et al; RIETE investigators. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 2017; 130 (03) 337-347
3 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110 (10) 2339-2346
4 Cronin-Fenton DP, Søndergaard F, Pedersen LA. , et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103 (07) 947-953
5 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
6 Gade IL, Braekkan SK, Naess IA. , et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost 2017; 15 (08) 1567-1575
7 Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006; 42 (03) 410-414
8 Cubilla AL, Fitzgerald PJ. Cancer of the exocrine pancreas: the pathologic aspects. CA Cancer J Clin 1985; 35 (01) 2-18
9 Mandalà M, Reni M, Cascinu S. , et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18 (10) 1660-1665
10 Oh SY, Kim JH, Lee K-W. , et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 2008; 122 (04) 485-490
11 Pinzon R, Drewinko B, Trujillo JM, Guinee V, Giacco G. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center. J Clin Oncol 1986; 4 (04) 509-514
12 Mitry E, Taleb-Fayad R, Deschamps A. , et al. Risk of venous thrombosis in patients with pancreatic adenocarcinoma. Gastroenterol Clin Biol 2007; 31 (12) 1139-1142
13 Epstein AS, Soff GA, Capanu M. , et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 2012; 118 (12) 3053-3061
14 Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. Clin Transl Oncol 2014; 16 (10) 927-930
15 Krepline AN, Christians KK, George B. , et al. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-is it indicated?. J Surg Oncol 2016; 114 (05) 581-586
16 Lee J-C, Ro YS, Cho J. , et al. Characteristics of venous thromboembolism in pancreatic adenocarcinoma in East Asian ethnics: a large population-based observational study. Medicine (Baltimore) 2016; 95 (17) e3472
17 Kruger S, Haas M, Burkl C. , et al. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer-a retrospective cohort study. Thromb Res 2017; 157: 9-15
18 van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res 2017; 150: 30-32
19 Mikal S, Campbell AJA. Carcinoma of the pancreas; diagnostic and operative criteria based on 100 consecutive autopsies. Surgery 1950; 28 (06) 963-969
20 Bikdeli B, Jimenez D, Hawkins M. , et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
21 Louzada ML, Carrier M, Lazo-Langner A. , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
22 Chee CE, Ashrani AA, Marks RS. , et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014; 123 (25) 3972-3978
23 Farge D, Bounameaux H, Brenner B. , et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17 (10) e452-e466
24 Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011; 106 (02) 371-378
25 Larsen AC, Brøndum Frøkjaer J, Wishwanath Iyer V. , et al. Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors. J Thromb Haemost 2015; 13 (04) 555-562
26 Khorana AA, Ahrendt SA, Ryan CK. , et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13 (10) 2870-2875
27 Khorana AA, Francis CW, Menzies KE. , et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6 (11) 1983-1985
28 Khorana AA, Kamphuisen PW, Meyer G. , et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH Trial. J Clin Oncol 2017; 35 (10) 1078-1085
29 Prandoni P, Lensing AWA, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
30 Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. Thromb Res 2016; 140 (Suppl. 01) S93-S98
31 Alatri A, Mazzolai L, Font C. , et al. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry. Thromb Haemost 2017; 117 (08) 1630-1636